This video examines phase II results of a single-arm trial that tested checkpoint inhibition plus the IDO–pathway inhibitor indoximod in patients with melanoma.
Yousef N. Zakharia, MD
Advertisement
Articles by Yousef N. Zakharia, MD
Advertisement
Latest Updated Articles
Adding Indoximod to Pembrolizumab Improved Response Rate in Advanced MelanomaPublished: April 5th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
2
Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?
3
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
4
Identifying Common Toxicities with Targeted Therapies in GI Malignancies
5
